Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
WIG-2404
- Development stage
- Preclinical
- Lead developer
- WhanIn Pharm
- Modality
- Small Molecules
01
Overview
WIG-2404 is an investigational drug candidate being developed by Whanin Pharmaceutical, a South Korean pharmaceutical company specializing in central nervous system (CNS) disorders. It is currently in development for the treatment of depression. As part of Whanin's R&D pipeline, WIG-2404 represents the company's ongoing efforts to expand its neuropsychiatry portfolio. While specific details regarding its chemical structure, molecular target, and exact clinical phase have not been extensively disclosed in public corporate materials, it is categorized alongside other CNS-focused candidates in the company's development strategy.
Beyond the preview
Go deeper on WIG-2404.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on WIG-2404.